MYNZ (Mainz Biomed NV) FCF Margin % : 0.00% (As of Jun. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Mainz Biomed NV FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Mainz Biomed NV's Free Cash Flow for the three months ended in Jun. 2024 was $0.00 Mil. Mainz Biomed NV's Revenue for the three months ended in Jun. 2024 was $0.00 Mil. Therefore, Mainz Biomed NV's FCF Margin % for the quarter that ended in Jun. 2024 was 0.00%.

As of today, Mainz Biomed NV's current FCF Yield % is -225.85%.

The historical rank and industry rank for Mainz Biomed NV's FCF Margin % or its related term are showing as below:

MYNZ' s FCF Margin % Range Over the Past 10 Years
Min: -2910.94 Med: -561.01 Max: -96.96
Current: -2660.49

During the past 5 years, the highest FCF Margin % of Mainz Biomed NV was -96.96%. The lowest was -2910.94%. And the median was -561.01%.

MYNZ's FCF Margin % is ranked worse than
96.76% of 216 companies
in the Medical Diagnostics & Research industry
Industry Median: -5.655 vs MYNZ: -2660.49

Mainz Biomed NV FCF Margin % Historical Data

The historical data trend for Mainz Biomed NV's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mainz Biomed NV FCF Margin % Chart

Mainz Biomed NV Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

FCF Margin %

-148.04

-96.96

-561.01

-2,910.94

-2,663.46

Mainz Biomed NV Quarterly Data
	Dec19	Jun20	Dec20	Jun21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Jun24
FCF Margin %	Get a 7-Day Free Trial									-2,824.00	-2,105.62	-3,636.26	-2,286.98	-

Competitive Comparison of Mainz Biomed NV's FCF Margin %

For the Diagnostics & Research subindustry, Mainz Biomed NV's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Mainz Biomed NV's FCF Margin % Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Mainz Biomed NV's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Mainz Biomed NV's FCF Margin % falls into.

Mainz Biomed NV FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Mainz Biomed NV's FCF Margin for the fiscal year that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	-23.838	/	0.895
	=	-2,663.46 %

Mainz Biomed NV's FCF Margin for the quarter that ended in Jun. 2024 is calculated as

FCF Margin	=	Free Cash Flow (Q: Jun. 2024 )	/	Revenue (Q: Jun. 2024 )
	=	0	/	0
	=	%

Mainz Biomed NV FCF Margin % Related Terms

Thank you for viewing the detailed overview of Mainz Biomed NV's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Mainz Biomed NV Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Mainz Biomed NV (NAS:MYNZ) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

4TO:Germany

Address

Robert Koch Strasse 5, Sirius Gutenberg Park, Mainz, RP, DEU, 55129

Website

https://www.mainzbiomed.com

Mainz Biomed NV develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The company's flagship product is ColoAlert, is an accurate, non-invasive and easy-to-use, early-detection diagnostic test for colorectal cancer based on real-time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in stool samples.